|
|
|
|
YOU AND ADMERITOX
YOU are involved in preclinical development, scientific writing or regulatory
submission of human or veterinary drugs.
You are dealing with a particular issue and you are looking for the appropriate person(s)
to team up with, to find the solution.
ADMERITOX is a consultancy, dedicated to the following services:
- preclinical development strategy;
- operational support for preclinical
study design, selection of Contract Research Organization and study monitoring;
- scientific writing of preclinical
study reports, publications, position papers and documents for regulatory submission.
ADMERITOX is Ria Vos, PhD
Ria Vos has more than 13
years of experience in preclinical development (ADME, safety pharmacology and toxicology)
of pharmaceuticals. Her expertise includes virtually all aspects of preclinical development,
ranging from the design of the preclinical program, to supervision, monitoring and
reporting of the various preclinical studies, and the writing of the preclinical
parts of regulatory documents such as the Common Technical Document.
After a PhD in Toxicology and Biochemistry (Agricultural University of Wageningen,
The Netherlands), Ria Vos joined the pharmaceutical company Organon in The Netherlands.
She was manager of the ADME group, study director of ADME studies and a member of
various Development Project Teams for 7 years. She then became manager of the preclinical
International Project Team Representatives, where she supervised the preparation
and implementation of preclinical (ADME and toxicological) development strategies,
the safety evaluations prior to the start of "first" clinical studies,
and the preclinical contributions to position papers and regulatory documents. After
five years in that position, she moved to France for family reasons. She started
working as a preclinical consultant early 2004.
Ria Vos has participated in preclinical programs for more than 40 projects,
covering several therapeutic areas and routes of administration. In addition, she
has had the opportunity to contribute to various meetings with the FDA and to international
and multidisciplinary cooperations with a number of different pharmaceutical companies.
You can download and print the content of this website as admeritox.doc or admeritox.pdf
|
|
|
|
